Publication | Closed Access

Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy

Hematological MalignancyLymphoid NeoplasiaSlowest RateMedicineMixed-phenotype Acute LeukemiaHematologyPediatricsPathologyAdult T-cell Leukemia-lymphomaOncologyInduction TherapyMinimal Residual Disease